Skip to main content

Articles By Jack Cush, MD

OAI010_0.jpg

Outcome of Pain in Hand Osteoarthritis

Leiden cohort study of hand osteoarthritis (HOA) patients shows that over 4 years, pain outcomes are variable, and not inevitably worsening.

Read Article
GCA temporal artery

Drug-Free Remission in Giant Cell Arteritis is Uncommon

A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR).

Read Article
young%20doctors.jpg (keep)

Way Behind in Pediatric Rheumatology

While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP). 

Read Article
mosquito.jpg

Chikungunya marches on, at a cost

A recent article from BMC Global Health suggests that between 2011 and 2020, the mosquito-borne disease chikungunya, has disabled millions and likely amassed close to $50 billion in healthcare and disability-related costs in 110 countries. 

Read Article
RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
DLE discoid lupus

Challenge in Measuring Cutaneous Lupus Activity and Severity

JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

Read Article
IgG4.criteria.jpg

Inebilizumab for Treatment of IgG4-Related Disease

Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.

Read Article
eyes

Phase 2b Study of Ianalumab in Sjögren's

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

Read Article
Roundup cover

ACR24: Rheumatology Roundup

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article
Best of

#ACR Best 2024 - Day 4

Although the last day of ACR Convergence 2024 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today.  As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.

Read Article
×